The latest health and pharmaceuticals industry and company news and analysis from FriedlNews
Page 1/9

Austrian Health and Pharma Headlines

Antibiotics Company Nabriva Therapeutics Collects USD 120 Mln from Investors

Viennese biotech firm Nabriva Therapeutics, specialized in antibiotics against resistant bacteria, has collected USD 120 million from investors. The financing process took two tranches, law firm Wolf Theiss, which advised investors together with US firm Cooley, announced on Wednesday.

April 9, 2015

Vamed to Manage First Hospital in China

Vamed is about to establish and manage its first hospital in China - in the provincial capital Haikou on the island of Hainan.

March 30, 2015

Valneva Biotech Target Price Cut to EUR 4.9, 'Hold' Maintained

Listed vaccine producer Valneva, formerly Intercell, had its target price reduced slightly to EUR 4.9 (USD 5.3) from EUR 5.1 with the recommendation kept at 'hold' at Erste Group.

March 9, 2015

Online Pharmacies: Dispatch of OTC Medication in Austria Allowed

As of 25 June 2015 Austrian pharmacies are allowed to sell over-the-counter pharmaceuticals online. The basis for Austrian regulations is the Falsified Medicines Directive, already transposed into Austrian law. In a regulation yet to get an opinion, duties of pharmacies will be determined.

March 3, 2015

Valneva Biotech Reduces 2014 EBITDA Loss to EUR 7.4 Mln

Listed vaccine produce Valneva, formerly Intercell, posted a preliminary EUR 7.4 million (USD 8.4 million) EBITDA loss in 2014, better than EUR 11.7 million loss a year earlier, the company said Thursday.

February 26, 2015

Health Insurance Industry Expects EUR 129 Million Deficit

Austria’s health insurance fund managers expect after several years of surplus to generate a deficit again this year. According to the latest estimates of the Chief Association of Social Insurance Agencies (Hauptverband der Sozialversicherungsträger) the deficit might reach EUR 128.9 million (USD 147 million) in 2015, which marks a hefty drop from last year’s surplus of EUR 83 million (USD 94.9 million).

February 16, 2015

Valneva Completes EUR 45 Million Capital Increase

The listed biotechnology company Valneva SE announces the completion of its capital increase with shareholders preferential subscription rights launched on January 12th, 2015. Valneva estimates net proceeds of EUR 42 millions from 18.2 million offered new shares. The new ordinary shares will be traded on Euronext and on the Prime Market segment of the Vienna Stock Exchange. The financing will mainly be used for the acquisition of Crucell Sweden AB and all assets, licenses and privileges related to Dukoral.

February 4, 2015

Pfizer's Agreement To Acquire Baxter’s Portfolio Of Marketed Vaccines Includes Facility in Austria

Pfizer Inc. announced that it has entered into a definitive agreement to acquire Baxter International Inc.’s portfolio of marketed vaccines for $635 million. As part of the transaction, Pfizer will also acquire a portion of Baxter’s facility in Orth, Austria, where these vaccines are manufactured.

August 1, 2014

Semperit to Realign Rubber Glove Production in Thailand

Listed chemicals group Semperit is realigning its rubber glove production activities in Thailand, i.e. the 50:50 joint venture with the Thai partner Sri Trang which runs a glove plant, Semperit said. The distribution will be realigned as of the turn of 2014 and 2015, while Semperit is also attempting to push through its rights in the JV at court, the company added.

July 18, 2014

Austrian Export Award 2014 for Above-Average Export Commitment

As part of a festive gala evening in Vienna's Museumsquartier, the Austrian Export Prize 2014 has been awarded by the Federal Minister for Science, Research and Economics, Reinhold Mitterlehner, and the President of the Economic Chamber Austria (WKO) Christoph Leitl.

June 26, 2014